Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Decision-making on malaria vaccine introduction: the role of cost-effectiveness analyses.

Moorthy VS, Hutubessy R, Newman RD, Hombach J.

Bull World Health Organ. 2012 Nov 1;90(11):864-6. doi: 10.2471/BLT.12.107482. No abstract available.

2.

Policy challenges in malaria vaccine introduction.

Moree M, Ewart S.

Am J Trop Med Hyg. 2004 Aug;71(2 Suppl):248-52.

3.

Advanced purchase commitments for a malaria vaccine.

[No authors listed]

Natl Bur Econ Res Bull Aging Health. 2005 Summer;(12):1-2. No abstract available.

PMID:
16175672
4.

The evidence base on the cost-effectiveness of malaria control measures in Africa.

Goodman CA, Mills AJ.

Health Policy Plan. 1999 Dec;14(4):301-12. Review.

5.

Costing RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: A generalizable approach drawing on publicly available data.

Galactionova K, Bertram M, Lauer J, Tediosi F.

Vaccine. 2015 Nov 27;33(48):6710-8. doi: 10.1016/j.vaccine.2015.10.079.

6.

Predicting the cost-effectiveness of introducing a pre-erythrocytic malaria vaccine into the expanded program on immunization in Tanzania.

Tediosi F, Hutton G, Maire N, Smith TA, Ross A, Tanner M.

Am J Trop Med Hyg. 2006 Aug;75(2 Suppl):131-43.

7.

Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation.

Moorthy V, Reed Z, Smith PG; WHO Study Group on Measures of Malaria Vaccine Efficacy..

Vaccine. 2007 Jul 9;25(28):5115-23.

PMID:
17577487
8.

WHO policy development processes for a new vaccine: case study of malaria vaccines.

Milstien J, Cárdenas V, Cheyne J, Brooks A.

Malar J. 2010 Jun 24;9:182. doi: 10.1186/1475-2875-9-182.

9.

Phase 3: RTS,S almost halves malaria cases in young children.

Riedmann EM.

Hum Vaccin Immunother. 2013 Dec;9(12):2501. No abstract available.

PMID:
24716207
10.

Vaccines against asexual stage malaria parasites.

Kumar S, Epstein JE, Richie TL.

Chem Immunol. 2002;80:262-86. Review. No abstract available.

PMID:
12058644
11.

Malaria vaccine trials.

Greenwood B, Alonso P.

Chem Immunol. 2002;80:366-95. Review. No abstract available.

PMID:
12058650
12.

Malaria vaccine development using synthetic peptides as a technical platform.

Corradin G, Céspedes N, Verdini A, Kajava AV, Arévalo-Herrera M, Herrera S.

Adv Immunol. 2012;114:107-49. doi: 10.1016/B978-0-12-396548-6.00005-6. Review.

PMID:
22449780
13.

European Vaccine Initiative: lessons from developing malaria vaccines.

Geels MJ, Imoukhuede EB, Imbault N, van Schooten H, McWade T, Troye-Blomberg M, Dobbelaer R, Craig AG, Leroy O.

Expert Rev Vaccines. 2011 Dec;10(12):1697-708. doi: 10.1586/erv.11.158. Review.

PMID:
22085173
14.

Simulation of the cost-effectiveness of malaria vaccines.

Tediosi F, Maire N, Penny M, Studer A, Smith TA.

Malar J. 2009 Jun 8;8:127. doi: 10.1186/1475-2875-8-127.

15.

Impact of pre-existing MSP1(42)-allele specific immunity on potency of an erythrocytic Plasmodium falciparum vaccine.

Bergmann-Leitner ES, Duncan EH, Mease RM, Angov E.

Malar J. 2012 Sep 7;11:315. doi: 10.1186/1475-2875-11-315.

16.

RTS,S/AS01 partially successful in preventing malaria in children.

[No authors listed]

Hum Vaccin Immunother. 2015;11(6):1298. doi: 10.1080/21645515.2015.1056660. No abstract available.

17.

Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa.

Leach A, Vekemans J, Lievens M, Ofori-Anyinam O, Cahill C, Owusu-Agyei S, Abdulla S, Macete E, Njuguna P, Savarese B, Loucq C, Ballou WR; Clinical Trials Partnership Committee..

Malar J. 2011 Aug 4;10:224. doi: 10.1186/1475-2875-10-224.

18.

Malaria vaccines: from the laboratory to the field.

Genton B, Corradin G.

Curr Drug Targets Immune Endocr Metabol Disord. 2002 Oct;2(3):255-67. Review.

PMID:
12476490
19.

Strength in unity.

Moree M, Ewart S, Diggs C.

Nature. 2004 Aug 19;430(7002):938-9. No abstract available.

PMID:
15318238
20.

Optimal vaccination and bednet maintenance for the control of malaria in a region with naturally acquired immunity.

Prosper O, Ruktanonchai N, Martcheva M.

J Theor Biol. 2014 Jul 21;353:142-56. doi: 10.1016/j.jtbi.2014.03.013.

PMID:
24641821
Items per page

Supplemental Content

Support Center